Current Report Filing (8-k)
December 23 2021 - 5:01PM
Edgar (US Regulatory)
0000908259
false
0000908259
2021-12-21
2021-12-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
December
21, 2021
ONCOTELIC
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-21990
|
|
13-3679168
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
29397
Agoura Road, Suite 107
Agoura
Hills, CA 91301
(Address
of principal executive offices and Zip Code)
Registrant’s
telephone number, including area code
(650)
635-7000
Not
applicable.
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of class
|
|
Trading
Symbols
|
|
Name
of each exchange on which registered
|
N/A
|
|
OTLC
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
4.01
|
Change
in Registrant’s Certifying Accountant.
|
(a)
On December 21, 2021, the Board of Directors of Oncotelic Therapeutics, Inc. (the “Company”), approved the
engagement of Rose, Snyder & Jacobs, LLP (“RSJ”) as the Company’s independent registered public
accounting firm for the Company’s fiscal year ended December 31, 2021, effective immediately, and dismissed Baker Tilly US LLP
(“Baker Tilly”) as the Company’s independent registered public accounting firm.
Baker
Tilly’s audit reports on the Company’s consolidated financial statements as of and for the fiscal years ended December 31,
2020 and 2019 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit
scope or accounting principles, except that the audit reports for the years ended December 31, 2020 and 2019 contained an explanatory
paragraph disclosing the uncertainty regarding the Company’s ability to continue as a going concern.
During
the fiscal years ended December 31, 2020, and 2019, and the subsequent interim periods through December 21, 2021, there were (i) no disagreements
(as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Baker Tilly on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Baker
Tilly’s satisfaction, would have caused Baker Tilly to make reference thereto in their reports on the financial statements for
such years, and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S- K.
The
Company provided Baker Tilly with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that Baker
Tilly furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made
herein. A copy of Baker Tilly’s letter dated December 21, 2021, is filed as Exhibit 16.1 hereto.
(b)
During the fiscal years ended December 31, 2020, and 2019, and the subsequent interim periods through December 21, 2021, neither the
Company nor anyone acting on its behalf has consulted with RSJ regarding (i) the application of accounting principles to a specific
transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial
statements or the effectiveness of internal control over financial reporting, and neither a written report or oral advice was
provided to the Company that RSJ concluded was an important factor considered by the Company in reaching a decision as to any
accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of
Item 304(a)(1)(iv) of Regulation S-K, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation
S-K.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Oncotelic
Therapeutics, Inc.
|
|
|
|
Date:
December 23, 2021
|
By:
|
/s/
Vuong Trieu
|
|
|
Vuong
Trieu
|
|
|
Chief
Executive Officer
|
Oncotelic Therapeutics (QB) (USOTC:OTLC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncotelic Therapeutics (QB) (USOTC:OTLC)
Historical Stock Chart
From Apr 2023 to Apr 2024